Blue Earth Diagnostics will highlight study results for its experimental PET radiotracer F-18 rhPSMA-7.3 at the American Society for Radiation Oncology (ASTRO) 2022 annual meeting being held October 23 to 26 in San Antonio, TX.
The company plans to tout findings from its phase III SPOTLIGHT study, which evaluated the impact of clinical factors on the detection rate of F-18 rhPSMA-7.3 PET imaging in men with suspected prostate cancer recurrence, based on elevated prostate-specific antigen (PSA) levels.
In addition, Blue Earth will highlight research about the tracer fluciclovine F-18 (Axumin) that will include interim analyses from a randomized trial using it and gallium-68 (Ga-68) PSMA PET/CT in postprostatectomy radiotherapy, findings on the prognostic utility of PET using Axumin after radiotherapy, and timing and patterns of potential recurrences after stereotactic body radiation therapy for localized prostate cancer, it said.
